



**MYDECINE™**  
M E D I C I N E E V O L V E D

Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine.

*Agreement allowing work on numerous collaborative research initiatives in the coming years*

DENVER, August 18, 2021 — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announces it has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, with research to be led by Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University, Dr. Matthew W. Johnson, Ph. D. The Johns Hopkins Behavioral Pharmacology Research Unit has extensive experience conducting clinical research related to therapeutic use of psychedelics.

Mydecine CEO Josh Barch said “We are excited to expand on the current work we are conducting with Dr. Matt Johnson and his team at JHU in regards to smoking cessation to include numerous other projects over the next five years. The researchers at JHU have proven their incredible depth of knowledge in the field.”

“The long-term potential of this research agreement is captivating for us here at Mydecine,” Chief Scientific Officer and Co-Founder of Mydecine, Rob Roscow, stated. “It demonstrates our commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.”

This agreement allows Johns Hopkins University and Mydecine to further collaborate to advance research, on novel psychedelic therapies to treat mental health and addiction disorders.

“Despite the recent attention to opiate and dependence on other illicit substances, we sometimes forget about the incredible burden that nicotine dependence has on our societies,” said Dr. Rakesh Jetly, Chief Medical Officer, Mydecine. “According to [the CDC](#), cigarette smoking is the leading cause of preventable disease and death in the United States, killing more than 480,000 Americans each year. Despite all the public education and dire warnings, cigarette smoking remains one of the most difficult addiction to treat and contributes to more deaths than all the other substances combined, making research like this vital.”

#### **About Mydecine Innovations Group**

Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics,

novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

Learn more at: <https://www.mydecine.com/> and follow us on [Facebook](#), [Twitter](#), and [Instagram](#).

**For more information, please contact:**

**Media Contact**

Courtney Ryan  
LS2group  
cryan@ls2group.com  
515-770-4823

**Investor Contacts**

Charles Lee, Investor Relations  
corp@mydecineinc.com  
1-720-277-9879

Allison Soss / Erika Kay  
KCSA Strategic Communications  
myco@kcsa.com  
1-212-896-1267

**On behalf of the Board of Directors:**

Joshua Bartch, Chief Executive Officer [contact@mydecineinc.com](mailto:contact@mydecineinc.com)

**For further information about Mydecine Innovations Group, Inc., please visit the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) or visit the Company's website at [www.mydecine.com](http://www.mydecine.com).**

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management's current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the

date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.